150 related articles for article (PubMed ID: 22171616)
1. Characterization of in vivo disulfide-reduction mediated drug release in mouse kidneys.
Yang JJ; Kularatne SA; Chen X; Low PS; Wang E
Mol Pharm; 2012 Feb; 9(2):310-7. PubMed ID: 22171616
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of disulfide reduction during receptor-mediated endocytosis by using FRET imaging.
Yang J; Chen H; Vlahov IR; Cheng JX; Low PS
Proc Natl Acad Sci U S A; 2006 Sep; 103(37):13872-7. PubMed ID: 16950881
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and biological evaluation of a folate-targeted rhaponticin conjugate.
Liang X; Sun Y; Zeng W; Liu L; Ma X; Zhao Y; Fan J
Bioorg Med Chem; 2013 Jan; 21(1):178-85. PubMed ID: 23177726
[TBL] [Abstract][Full Text] [Related]
4. Regioselective synthesis of folate receptor-targeted agents derived from epothilone analogs and folic acid.
Vlahov IR; Vite GD; Kleindl PJ; Wang Y; Santhapuram HK; You F; Howard SJ; Kim SH; Lee FF; Leamon CP
Bioorg Med Chem Lett; 2010 Aug; 20(15):4578-81. PubMed ID: 20594844
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and biological evaluation of folate receptor-targeted boronated PAMAM dendrimers as potential agents for neutron capture therapy.
Shukla S; Wu G; Chatterjee M; Yang W; Sekido M; Diop LA; Müller R; Sudimack JJ; Lee RJ; Barth RF; Tjarks W
Bioconjug Chem; 2003; 14(1):158-67. PubMed ID: 12526705
[TBL] [Abstract][Full Text] [Related]
6. In search of the Holy Grail: Folate-targeted nanoparticles for cancer therapy.
Garcia-Bennett A; Nees M; Fadeel B
Biochem Pharmacol; 2011 Apr; 81(8):976-84. PubMed ID: 21300030
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and biological evaluation of EC72: a new folate-targeted chemotherapeutic.
Leamon CP; Reddy JA; Vlahov IR; Vetzel M; Parker N; Nicoson JS; Xu LC; Westrick E
Bioconjug Chem; 2005; 16(4):803-11. PubMed ID: 16029021
[TBL] [Abstract][Full Text] [Related]
8. Real time, noninvasive imaging and quantitation of the accumulation of ligand-targeted drugs into receptor-expressing solid tumors.
Vlashi E; Sturgis JE; Thomas M; Low PS
Mol Pharm; 2009; 6(6):1868-75. PubMed ID: 19754150
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and in vitro/in vivo evaluation of 99mTc-labeled folate conjugates for folate receptor imaging.
Lu J; Pang Y; Xie F; Guo H; Li Y; Yang Z; Wang X
Nucl Med Biol; 2011 May; 38(4):557-65. PubMed ID: 21531293
[TBL] [Abstract][Full Text] [Related]
10. Folic acid modified cationic γ-cyclodextrin-oligoethylenimine star polymer with bioreducible disulfide linker for efficient targeted gene delivery.
Zhao F; Yin H; Zhang Z; Li J
Biomacromolecules; 2013 Feb; 14(2):476-84. PubMed ID: 23323627
[TBL] [Abstract][Full Text] [Related]
11. Targeting folate receptors to treat invasive urinary bladder cancer.
Dhawan D; Ramos-Vara JA; Naughton JF; Cheng L; Low PS; Rothenbuhler R; Leamon CP; Parker N; Klein PJ; Vlahov IR; Reddy JA; Koch M; Murphy L; Fourez LM; Stewart JC; Knapp DW
Cancer Res; 2013 Jan; 73(2):875-84. PubMed ID: 23204225
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and evaluation of a novel lipophilic folate receptor targeting ligand.
Liu Y; Xu S; Teng L; Yung B; Zhu J; Ding H; Lee RJ
Anticancer Res; 2011 May; 31(5):1521-5. PubMed ID: 21617205
[TBL] [Abstract][Full Text] [Related]
13. The intracellular controlled release from bioresponsive mesoporous silica with folate as both targeting and capping agent.
Guo R; Li LL; Zhao WH; Chen YX; Wang XZ; Fang CJ; Feng W; Zhang TL; Ma X; Lu M; Peng SQ; Yan CH
Nanoscale; 2012 Jun; 4(11):3577-83. PubMed ID: 22543578
[TBL] [Abstract][Full Text] [Related]
14. Delivery of zoledronic acid encapsulated in folate-targeted liposome results in potent in vitro cytotoxic activity on tumor cells.
Shmeeda H; Amitay Y; Gorin J; Tzemach D; Mak L; Ogorka J; Kumar S; Zhang JA; Gabizon A
J Control Release; 2010 Aug; 146(1):76-83. PubMed ID: 20462513
[TBL] [Abstract][Full Text] [Related]
15. Folate receptor-specific antitumor activity of EC131, a folate-maytansinoid conjugate.
Reddy JA; Westrick E; Santhapuram HK; Howard SJ; Miller ML; Vetzel M; Vlahov I; Chari RV; Goldmacher VS; Leamon CP
Cancer Res; 2007 Jul; 67(13):6376-82. PubMed ID: 17616697
[TBL] [Abstract][Full Text] [Related]
16. Characterization of the pH of folate receptor-containing endosomes and the rate of hydrolysis of internalized acid-labile folate-drug conjugates.
Yang J; Chen H; Vlahov IR; Cheng JX; Low PS
J Pharmacol Exp Ther; 2007 May; 321(2):462-8. PubMed ID: 17289839
[TBL] [Abstract][Full Text] [Related]
17. Ligand binding and kinetics of folate receptor recycling in vivo: impact on receptor-mediated drug delivery.
Paulos CM; Reddy JA; Leamon CP; Turk MJ; Low PS
Mol Pharmacol; 2004 Dec; 66(6):1406-14. PubMed ID: 15371560
[TBL] [Abstract][Full Text] [Related]
18. [Folate receptor-mediated antitumor drugs].
Zhao J; Cao SL; Zheng XL; Zhao B
Yao Xue Xue Bao; 2009 Feb; 44(2):109-14. PubMed ID: 19408677
[TBL] [Abstract][Full Text] [Related]
19. Folate receptor specific anti-tumor activity of folate-mitomycin conjugates.
Reddy JA; Westrick E; Vlahov I; Howard SJ; Santhapuram HK; Leamon CP
Cancer Chemother Pharmacol; 2006 Aug; 58(2):229-36. PubMed ID: 16331500
[TBL] [Abstract][Full Text] [Related]
20. Peptide-drug conjugate linked via a disulfide bond for kidney targeted drug delivery.
Geng Q; Sun X; Gong T; Zhang ZR
Bioconjug Chem; 2012 Jun; 23(6):1200-10. PubMed ID: 22663297
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
